Nima Farzan, Kinnate CEO
Kinnate gets $98M Series C to push precision oncology drugs to the clinic
Less than a year after banking $74.5 million in a Series B, San Diego-based Kinnate Biopharma is following up with a Series C to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.